The Effect of Preoperative Intravenous Ferric Derisomaltose and EPO and Tranexamic Acid in Patients With Preoperative Anemia or Iron Deficiency in Bone Tumor

NCT07314424 | Not Yet Recruiting Phase 4

• 1 other identifier: PKUPH-anemia-001
• Study Type: interventional
• Target: 160
• Locations: 0 countries
• Sites: N/A

Brief Summary

The pelvis and spine are common sites of primary and secondary bone tumors, and most patients require surgical treatment. However, due to bleeding, high tumor burden, and other reasons, iron deficiency anemia (IDA) is common in these patients. At present, allogeneic blood resources are scarce in China and even globally, and cancer patients cannot undergo autologous blood transfusion. In addition, there is a large amount of bleeding during pelvic and spinal open surgery, which collectively leads to a high incidence of perioperative anemia in patients with pelvic and spinal tumors, and even the loss of surgical opportunities. Therefore, perioperative blood management for bone tumor surgery is extremely important. The combination of intravenous iron and EPO has been proven to rapidly improve the hemoglobin levels of perioperative surgical patients in previous studies, but there is currently no research related to bone tumors. This study uses a single center, prospective, open label, randomized controlled clinical trial to explore the effects of preoperative application of intravenous isomaltose iron combined with erythropoietin and tranexamic acid compared to conventional treatment in patients with preoperative anemia or iron deficiency in bone tumor surgery, hoping to establish a standard paradigm for perioperative blood management in bone tumor patients.

Conditions

Anemia

Keywords

anemia; bone tumor; perioperative; Blood management

Outcome Measures

Primary Outcomes (1)

• Hb levels 21 days after surgery

  Day 21

Secondary Outcomes (2)

• Blood transfusion rate within 21 days after surgery

  Day 21

• Hb levels 14 days after surgery

  Day 14

Study Arms (2)

Isomaltose Anhydride Iron Group

EXPERIMENTAL

Calculate the patient's iron requirement based on a simplified scale for the isomaltose iron group; Yibiao 150IU/kg subcutaneous injection, no treatment in the conventional treatment group; 0.5g of tranexamic acid is administered locally after dilution before surgical closure

Drug: isomaltose iron

Conventional treatment group

NO INTERVENTION

Traditional symptomatic treatment

Interventions

isomaltose iron DRUG

Calculate the patient's iron requirement based on a simplified scale for the isomaltose iron group; Yibiao 150IU/kg subcutaneous injection, no treatment in the conventional treatment group; 0.5g of tranexamic acid is administered locally after dilution before surgical closure

Isomaltose Anhydride Iron Group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18 and above with primary malignant bone tumors and bone metastases who plan to undergo open surgery for the sacrum, pelvis, and spine.
• ± 2 days before surgery, hemoglobin\<130g/L, or iron deficiency (TSAT\<20%)
• Patients are able to understand the research content and sign informed consent forms

You may not qualify if:

• Meet any of the following criteria;
• Ferritin\>800 ng/ml or hemoglobin\<70 g/L
• Expected survival period less than six months
• Women who are pregnant, breastfeeding, or planning to conceive
• Known to have allergic reactions to other iron agents
• Severe bone marrow suppression event (4th degree bone marrow suppression) occurred 4 weeks before enrollment
• Decompensated stage of liver disease
• Patients with combined acute phase infections
• Chronic kidney disease stage 3-5
• Patients who received oral iron, intravenous iron, EPO, or blood transfusion treatment within one month prior to the start of the study.
• Researchers believe that other conditions that are not suitable for participation in this study, such as deafness, Parkinson's disease, communication disorders, etc
• Participated in other clinical trials within the three months prior to participating in this study

Sponsors & Collaborators

• Tang Xiaodong: lead

MeSH Terms

Conditions

Anemia; Bone Neoplasms

Condition Hierarchy (Ancestors)

Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms by Site; Neoplasms; Bone Diseases; Musculoskeletal Diseases

Central Study Contacts

Tang Xiaodong

CONTACT

010-88326196; tang15877@126.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: September 28, 2025
• First Posted: January 2, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2027
• Last Updated: January 2, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share